Abstract Number: 620 • 2018 ACR/ARHP Annual Meeting
Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)
Background/Purpose: The response rate of TNFis in RA is variable and to some extent unpredictable, making treatment decision-making quite complex. Some insurance carriers require RA…Abstract Number: 2066 • 2018 ACR/ARHP Annual Meeting
Serum IL-37 Is an Efficient Biomarker of Disease Activity and Treatment Response in Patients with Ankylosing Spondylitis
Background/Purpose: The measurement of disease activity is mainly dependent on the patient-reported outcome measures in ankylosing spondylitis (AS) patients. Current inflammatory biomarkers have insufficient sensitivity…Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…Abstract Number: 633 • 2016 ACR/ARHP Annual Meeting
High Similarity Between Ex-Vivo Inhibited Cytokine Profiling By Golimumab and Adalimumab As a Putative Explanation for Inferior Treatment Response to Golimumab after Adalimumab Failure in Rheumatoid Arthritis
Background/Purpose: Better prediction of treatment response to biologics in rheumatoid arthritis (RA) would contribute to optimal individualized treatment. Clinical data suggest that the response of…Abstract Number: 1617 • 2016 ACR/ARHP Annual Meeting
Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience both substantial fatigue and a decline in their health-related physical and emotional well-being. Sirukumab is a…Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…Abstract Number: 3011 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study
Long-term Outcomes After Disease Activity Guided Tapering of TNF Inhibitors in Rheumatoid Arthritis: 3 Year Data of a Randomized Controlled Pragmatic Non Inferiority Strategy Study…Abstract Number: 14L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Background/Purpose: The safety, efficacy, and dose response of ABT-494, a novel selective JAK1 inhibitor, were characterized vs placebo (PBO) in patients (pts) with moderately to…Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…Abstract Number: 1655 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Background/Purpose: Monotherapy accounts for approximately 30% of biologic disease-modifying anti-rheumatic drug (DMARD) use in RA (Emery P et al. Ann Rheum Dis 2013;72:1897-904). A validated…Abstract Number: 2842 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
Background/Purpose: Several studies have demonstrated that Tumor Necrosis Factor Inhibitors (TNFi) are efficient in non-radiographic axial spondyloarthritis (Nr-AxSpA). However, few investigations have directly compared ankylosing…Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting
Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA). Previous studies have suggested that circulating type I interferon (IFN)…Abstract Number: 2477 • 2014 ACR/ARHP Annual Meeting
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Background/Purpose Physicians, patients, and payers may have different ideas about what constitutes successful treatment and how treatment goals should be defined for rheumatoid arthritis (RA).…Abstract Number: 2279 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendations for Diagnosis and Management of Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS)
Background/Purpose Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking…Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…
ACR Meeting Abstracts